Insmed receives fda breakthrough therapy designation for brensocatib in patients with non-cystic fibrosis bronchiectasis

Insmed receives fda breakthrough therapy designation for brensocatib in patients with non-cystic fibrosis bronchiectasis (ncfbe).insmed inc - expects to initiate a phase 3 program for brensocatib in bronchiectasis in second half of 2020.

INSM Ratings Summary

INSM Quant Ranking